OKUR
OnKure Therapeutics, Inc.
Biotechnology
Market Cap$57M
5Y Perf.-97.1%
Build Your Comparison
Side-by-side financial analysisOKUR
KYMR
ARVN
JPM
Try popular comparisons:
Stock Comparison
OKUR vs KYMR vs ARVN vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
KYMR
Kymera Therapeutics, Inc.
Biotechnology
Market Cap$7.04B
5Y Perf.+89.3%
ARVN
Arvinas, Inc.
Biotechnology
Market Cap$489M
5Y Perf.-89.0%
JPM
JPMorgan Chase & Co.
Banks - Diversified
Market Cap$896.00B
5Y Perf.+108.5%
OKUR vs KYMR vs ARVN vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  OKUR |  KYMR |  ARVN |  JPM |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Banks - Diversified |
| Market Cap | $57M | $7.04B | $489M | $896.00B |
| Revenue (TTM) | $0.00 | $51M | $89M | $280.33B |
| Net Income (TTM) | $-44M | $-315M | $-221M | $57.05B |
| Gross Margin | — | 33.2% | 97.4% | 60.0% |
| Operating Margin | — | -7.0% | -279.3% | 25.9% |
| Forward P/E | — | — | — | 14.4x |
| Total Debt | $549K | $82M | $9M | $942.38B |
| Cash & Equiv. | $59M | $357M | $143M | $343.34B |
OKUR vs KYMR vs ARVN vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OKUR
KYMR
ARVN
JPM
| Stock | Apr 21 | Jun 26 | Return |
|---|---|---|---|
| OnKure Therapeutics… (OKUR) | 100 | 2.9 | -97.1% |
| Kymera Therapeutics… (KYMR) | 100 | 189.3 | +89.3% |
| Arvinas, Inc. (ARVN) | 100 | 11.0 | -89.0% |
| JPMorgan Chase & Co. (JPM) | 100 | 208.5 | +108.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OKUR vs KYMR vs ARVN vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: JPM leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and dividend income and shareholder returns. Kymera Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. OKUR also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
OKUR
OnKure Therapeutics, Inc.
The Growth Leader
OKUR is the clearest fit if your priority is growth.
- 84.4% revenue growth vs KYMR's -16.7%
Best for: growth
KYMR
Kymera Therapeutics, Inc.
The Income Pick
KYMR is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- beta 0.91
- Lower volatility, beta 0.91, Low D/E 5.2%, current ratio 10.47x
- Beta 0.91, current ratio 10.47x
- Beta 0.91 vs OKUR's 1.34
Best for: income & stability and sleep-well-at-night
ARVN
Arvinas, Inc.
The Growth Play
ARVN is the clearest fit if your priority is growth exposure.
- Rev growth -0.3%, EPS growth 53.8%, 3Y rev CAGR 26.0%
Best for: growth exposure
JPM
JPMorgan Chase & Co.
The Banking Pick
JPM carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 465.8% 10Y total return vs KYMR's 159.2%
- 20.4% margin vs KYMR's -6.1%
- 1.9% yield; 15-year raise streak; the other 3 pay no meaningful dividend
- 1.3% ROA vs OKUR's -41.5%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  OKUR | 84.4% revenue growth vs KYMR's -16.7% |
| Quality / Margins |  JPM | 20.4% margin vs KYMR's -6.1% |
| Stability / Safety |  KYMR | Beta 0.91 vs OKUR's 1.34 |
| Dividends | JPM | 1.9% yield; 15-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | KYMR | +82.3% vs ARVN's +0.1% |
| Efficiency (ROA) | JPM | 1.3% ROA vs OKUR's -41.5% |
OKUR vs KYMR vs ARVN vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
FY 2025
OKUR vs KYMR vs ARVN vs JPM — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLJPMLAGGINGARVN
Who Leads Where
JPM leads in 2 of 6 categories
KYMR leads 1 • OKUR leads 0 • ARVN leads 0 • 2 tied
Explore the data ↓ARVNArvinas, Inc.
0leads
OKUROnKure Therapeutics, …
0leads
KYMRKymera Therapeutics, …
1leads
JPMJPMorgan Chase & Co.
2leads
6 Total Categories
CATEGORYLEADERvs KYMRvs OKURMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
JPM4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
JPM6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
KYMR3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM and OKUR operate at a comparable scale, with $280.3B and $0 in trailing revenue. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to KYMR's -6.1%. On growth, KYMR holds the edge at +55.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | OKUROnKure Therapeuti… | KYMRKymera Therapeuti… |  ARVNArvinas, Inc. | JPMJPMorgan Chase & … |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $51M | $89M | $280.3B |
| EBITDAEarnings before interest/tax | -$61M | -$352M | -$245M | $81.4B |
| Net IncomeAfter-tax profit | -$44M | -$315M | -$221M | $57.0B |
| Free Cash FlowCash after capex | -$51M | -$244M | -$257M | $100.9B |
| Gross MarginGross profit ÷ Revenue | — | +33.2% | +97.4% | +60.0% |
| Operating MarginEBIT ÷ Revenue | — | -7.0% | -2.8% | +25.9% |
| Net MarginNet income ÷ Revenue | — | -6.1% | -2.5% | +20.4% |
| FCF MarginFCF ÷ Revenue | — | -4.7% | -2.9% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +55.5% | -91.7% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +6.7% | +13.4% | -178.9% | +16.0% |
JPM leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — OKUR and KYMR and ARVN each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | OKUROnKure Therapeuti… | KYMRKymera Therapeuti… | ARVNArvinas, Inc. | JPMJPMorgan Chase & … |
|---|---|---|---|---|
| Market CapShares × price | $57M | $7.0B | $489M | $896.0B |
| Enterprise ValueMkt cap + debt − cash | -$1M | $6.8B | $355M | $1.50T |
| Trailing P/EPrice ÷ TTM EPS | -0.95x | -23.36x | -5.92x | 16.00x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 14.40x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.90x |
| EV / EBITDAEnterprise value multiple | — | — | — | 18.36x |
| Price / SalesMarket cap ÷ Revenue | — | 179.54x | 1.86x | 3.20x |
| Price / BookPrice ÷ Book value/share | 1.01x | 4.61x | 1.13x | 2.47x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 8.88x |
Evenly matched — OKUR and KYMR and ARVN each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
JPM leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-45 for OKUR. OKUR carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), JPM scores 5/9 vs OKUR's 3/9, reflecting solid financial health.
| Metric | OKUROnKure Therapeuti… | KYMRKymera Therapeuti… | ARVNArvinas, Inc. | JPMJPMorgan Chase & … |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -45.3% | -25.0% | -44.4% | +15.9% |
| ROA (TTM)Return on assets | -41.5% | -22.3% | -28.4% | +1.3% |
| ROICReturn on invested capital | — | -24.9% | -22.4% | +4.5% |
| ROCEReturn on capital employed | -78.4% | -27.2% | -16.0% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.01x | 0.05x | 0.02x | 2.60x |
| Net DebtTotal debt minus cash | -$59M | -$275M | -$134M | $599.0B |
| Cash & Equiv.Liquid assets | $59M | $357M | $143M | $343.3B |
| Total DebtShort + long-term debt | $549,000 | $82M | $9M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | -5448.00x | -2119.53x | — | 0.74x |
JPM leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
KYMR leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $359 for OKUR. Over the past 12 months, KYMR leads with a +82.3% total return vs ARVN's +0.1%. The 3-year compound annual growth rate (CAGR) favors KYMR at 50.8% vs OKUR's -63.7% — a key indicator of consistent wealth creation.
| Metric | OKUROnKure Therapeuti… | KYMRKymera Therapeuti… | ARVNArvinas, Inc. | JPMJPMorgan Chase & … |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +41.9% | +18.5% | -33.9% | -0.5% |
| 1-Year ReturnPast 12 months | +47.4% | +82.3% | +0.1% | +21.8% |
| 3-Year ReturnCumulative with dividends | -95.2% | +242.9% | -73.7% | +138.2% |
| 5-Year ReturnCumulative with dividends | -96.4% | +70.4% | -91.0% | +118.2% |
| 10-Year ReturnCumulative with dividends | -97.2% | +159.2% | -52.8% | +465.8% |
| CAGR (3Y)Annualised 3-year return | -63.7% | +50.8% | -35.9% | +33.6% |
KYMR leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KYMR and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
KYMR is the less volatile stock with a 0.91 beta — it tends to amplify market swings less than OKUR's 1.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs ARVN's 52.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OKUROnKure Therapeuti… | KYMRKymera Therapeuti… | ARVNArvinas, Inc. | JPMJPMorgan Chase & … |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.34x | 0.91x | 1.14x | 0.94x |
| 52-Week HighHighest price in past year | $5.38 | $103.00 | $14.51 | $337.25 |
| 52-Week LowLowest price in past year | $1.91 | $36.65 | $6.06 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +78.1% | +83.7% | +52.2% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 53.8 | 56.8 | 24.1 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 210K | 492K | 794K | 7.0M |
Evenly matched — KYMR and JPM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: KYMR as "Buy", ARVN as "Buy", JPM as "Buy". Consensus price targets imply 94.6% upside for ARVN (target: $15) vs 5.9% for JPM (target: $340). JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.
| Metric | OKUROnKure Therapeuti… | KYMRKymera Therapeuti… | ARVNArvinas, Inc. | JPMJPMorgan Chase & … |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $112.60 | $14.75 | $339.75 |
| # AnalystsCovering analysts | — | 26 | 26 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +1.9% |
| Dividend StreakConsecutive years of raises | — | — | — | 15 |
| Dividend / ShareAnnual DPS | — | — | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +18.8% | +3.9% |
Insufficient data to determine a leader in this category.
Key Takeaway
JPM leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KYMR leads in 1 (Total Returns). 2 tied.
Best OverallJPMorgan Chase & Co. (JPM)Leads 2 of 6 categories
Loading custom metrics...
OKUR vs KYMR vs ARVN vs JPM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is OKUR or KYMR or ARVN or JPM a better buy right now?
For growth investors, JPMorgan Chase & Co.
(JPM) is the stronger pick with 3. 3% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Kymera Therapeutics, Inc. (KYMR) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OKUR or KYMR or ARVN or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +118. 2%, compared to -96. 4% for OnKure Therapeutics, Inc. (OKUR). Over 10 years, the gap is even starker: JPM returned +465. 8% versus OKUR's -97. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OKUR or KYMR or ARVN or JPM?
By beta (market sensitivity over 5 years), Kymera Therapeutics, Inc.
(KYMR) is the lower-risk stock at 0. 91β versus OnKure Therapeutics, Inc. 's 1. 34β — meaning OKUR is approximately 47% more volatile than KYMR relative to the S&P 500. On balance sheet safety, OnKure Therapeutics, Inc. (OKUR) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
04Which is growing faster — OKUR or KYMR or ARVN or JPM?
By revenue growth (latest reported year), JPMorgan Chase & Co.
(JPM) is pulling ahead at 3. 3% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Arvinas, Inc. grew EPS 53. 8% year-over-year, compared to -23. 8% for Kymera Therapeutics, Inc.. Over a 3-year CAGR, ARVN leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OKUR or KYMR or ARVN or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is OKUR or KYMR or ARVN or JPM more undervalued right now?
Analyst consensus price targets imply the most upside for ARVN: 94.
6% to $14. 75.
07Which pays a better dividend — OKUR or KYMR or ARVN or JPM?
In this comparison, JPM (1.
9% yield) pays a dividend. OKUR, KYMR, ARVN do not pay a meaningful dividend and should not be held primarily for income.
08Is OKUR or KYMR or ARVN or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Both have compounded well over 10 years (JPM: +465. 8%, OKUR: -97. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between OKUR and KYMR and ARVN and JPM?
These companies operate in different sectors (OKUR (Healthcare) and KYMR (Healthcare) and ARVN (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: OKUR is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; ARVN is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while OKUR, KYMR, ARVN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.